Image Credit: drlange/123rf.com
Tuberculosis (TB) continues to be a significant global health challenge, claiming the lives of over a million people annually. Traditionally, the diagnostic process has relied on examining phlegm samples under a microscope, a method that has not fundamentally changed since the 1880s. This approach presents several limitations, including the inability of some patients—such as children, the elderly, and those already suffering from other illnesses—to produce phlegm. Consequently, approximately half of all TB cases go undetected, and many patients often visit multiple health facilities before receiving a diagnosis.
In response to these challenges, Chinese biotech company Pluslife has introduced the MiniDock MTB, a portable diagnostic device designed to improve TB detection. The MiniDock MTB can utilize either a phlegm sample or a tongue swab, making it more versatile for patients unable to provide phlegm. The device operates by heating and spinning the sample to identify TB DNA, with a price point of $300 and test costs ranging from $3 to $4.
A recent study published in the New England Journal of Medicine evaluated the effectiveness of the MiniDock MTB across nearly 1,400 patients displaying TB symptoms in health centers across seven countries in Africa and Asia. The results indicated that both phlegm and tongue swab samples met the accuracy targets set by the World Health Organization (WHO), which had recommended the test shortly before the study’s publication.
Early detection of TB is critical, as it not only benefits the individual by initiating timely treatment but also plays a vital role in reducing disease transmission and preventing the development of antibiotic resistance. The recent advancements in TB diagnostics have been partly influenced by the surge in research and funding for swab-based testing methods during the COVID-19 pandemic. This newfound focus has brought much-needed attention to TB, a disease that has long been neglected.
Despite its promising capabilities, the MiniDock MTB does have limitations. Experts note that it may miss early-stage TB cases when the bacterial load is low and cannot differentiate between standard TB and drug-resistant strains, which necessitates additional testing. Nevertheless, the MiniDock MTB represents a significant step forward in making high-quality TB testing more accessible, addressing a critical gap in global health diagnostics that has persisted for over a century.
Check out the original article here: Source link
